CA 19-9

CA 19-9

abbreviation for cancer antigen 19-9 antigen, a blood tumor marker for pancreatic, hepatobiliary and colorectal cancer. This tumor marker is used in diagnosis, evaluation of a patient's response to treatment, and surveillance of the disease.

CA 19-9

A tumour-associated carbohydrate antigen located on the sialylated Lewis A blood group antigen (individuals who are genotypically Lewis a-b-[Lea-b-] comprise 5% of the population and cannot synthesize the antigen).

Serum levels
> 37 U/mL occur in 72–100% of patients with pancreatic cancer; 97% of those with levels > 1000 U/m; 65% of those with hepatocellular carcinoma; 20+% of those with gastric cancer; 20% of those with colorectal cancer. Because CA19-9 is also elevated in benign conditions (e.g., obstructive jaundice, liver disease, acute and chronic pancreatitis, diabetes, interstitial lung disease, collagen vascular disease, cholecystitis and cirrhosis of the liver), it is not widely used as a cancer marker. At one time it was regarded as useful in differentiating mesothelioma (in which it is negative) from various adenocarcinomas (in which it is positive).

CA 19-9 (Cancer antigen 19-9)

A tumor marker associated with pancreatic cancer.
Mentioned in: Tumor Markers
References in periodicals archive ?
However, inadequate sensitivity and specificity limit the use of CA 19-9 and CEA in the early screening and diagnosis of pancreatic cancer.
CA 19-9 was markedly elevated (18 860 U/mL; reference range = 0-70 U/mL).
8,9) However, elevated levels of CA 19-9 can also be detected in patients with nonmalignant diseases including pancreatic, liver, and biliary diseases.
Pancreatic cancer patients who didn't secrete CA 19-9 were also studied.
b) CA 19-9 in Pancreatic and gastric carcinomas, various carcinomas.
According to Emin u et al, 12 CA 19-9 the mean tumor size of patients with elevated CA 19-9 was greater than those with normal CA19-9 level (P = 0.
The relationships between tumor markers CEA CA 19-9 and stage of disease tumor differentiation presence of ringlet cell type presence of peritoneal carcinomatozis were investigated.
Spontaneously Ruptured Giant Splenic Cyst with Elevated Serum Levels of CA 19-9, CA 125 and Carcinoembryonic Antigen.
M High levels of CA 19-9 were subsequently reported in other gastrointestinal malignancies, including pancreas, bile duct, oesophageal and gastric cancer, as well as non-gastrointestinal tumours.
Elevated CA 19-9 level is typical for ductal pancreas adenocarcinoma; however, a slight increase of CA 19-9 levels can be observed in 20% of AIP patients as well, but rarely elevated above 200 U/ml [7, 10].
Distribution of blood group antigens and CA 19-9 in gastric cancers and non-neoplastic gastric mucosa.
11 for AFP, [beta]-hCG, CA 125, CA 15-3, CA 19-9 and CEA to determine whether the clinical information provided with the request corresponded to the BPAC guidelines of appropriate use.